SIBO and 12 groups of related diseases

Understanding Small Intestinal Bacterial Overgrowth and Its Far-Reaching Impact on Your Health

Small Intestinal Bacterial Overgrowth (SIBO) affects millions of people worldwide, yet many remain unaware of this condition and its profound connections to numerous health problems. Recent research has identified relationships between SIBO and 12 groups of related diseases, revealing that this digestive disorder may be influencing far more aspects of your health than previously understood.

What Is SIBO?

SIBO is a clinical condition characterized by excessive numbers of bacteria in the small intestine, primarily Gram-negative aerobic and anaerobic species. Under normal circumstances, your small intestine contains relatively few bacteria compared to your large intestine. However, when protective mechanisms fail—such as stomach acid production, intestinal motility, or the ileocecal valve function—bacteria can multiply excessively.

The condition manifests through various symptoms including:

• Chronic diarrhoea or constipation
• Bloating and abdominal pain
• Nutrient malabsorption
• Weight loss
• Fatigue and brain fog
• Vitamin deficiencies (particularly B12, B1, and B3)

The Twelve Disease Groups Connected to SIBO

1. Gastrointestinal Disorders: The Primary Connection

The strongest evidence links SIBO to various digestive conditions. Studies show SIBO occurs in over half of patients with Irritable Bowel Syndrome (IBS), with the bacterial overgrowth potentially driving IBS symptoms rather than simply accompanying them.

Key findings:

• 51.7% of IBS patients test positive for SIBO
• Inflammatory bowel diseases (Crohn’s and ulcerative colitis) show increased SIBO prevalence
• Non-alcoholic fatty liver disease (NAFLD) patients demonstrate 39% SIBO rates
• Over 50% of liver cirrhosis patients develop SIBO

2. Autoimmune Disease: The Systemic Sclerosis Link

Systemic sclerosis (SSc) patients experience SIBO at rates ten times higher than healthy individuals. The disease’s effect on intestinal motility creates ideal conditions for bacterial overgrowth, with duration of disease beyond five years significantly increasing SIBO risk.

Fecal calprotectin testing may help identify SSc patients at highest risk for SIBO, potentially enabling earlier intervention.

3. Cardiovascular System Diseases

Emerging research reveals concerning connections between SIBO and heart health. Patients with heart failure show altered intestinal function and increased intestinal permeability, allowing bacterial toxins to enter circulation. This endotoxin exposure contributes to inflammation and may worsen cardiac outcomes.

Research also suggests associations between SIBO and:

• Deep vein thrombosis
• Coronary artery disease
• Subclinical atherosclerosis

4. Metabolic Diseases: The Diabetes Connection

Both Type 1 and Type 2 diabetes show significantly higher SIBO rates compared to healthy populations. The relationship appears bidirectional—diabetes increases SIBO risk through mechanisms like diabetic neuropathy affecting gut motility, while SIBO may worsen glycemic control.

Particularly notable, gestational diabetes with concurrent SIBO correlates with higher blood glucose levels and increased newborn birth weight.

Metabolic disease findings:

• Hyperlipidemia patients show 78.9% SIBO prevalence
• Obesity increases SIBO risk two to threefold
• SIBO alters metabolism of fats and contributes to weight gain

Discover the reasons for your gut symptoms.

View our gut health tests

5. Endocrine Disorders: Thyroid Dysfunction

More than 50% of hypothyroidism patients experience SIBO. The thyroid-gut connection works through multiple pathways—thyroid hormones affect intestinal motility, while levothyroxine supplementation may paradoxically increase SIBO risk.

Bacterial antigens can potentially trigger autoimmune thyroid conditions like Hashimoto’s disease, highlighting the complex interplay between gut bacteria and thyroid function.

6. Nephrological Disorders: The Gut-Kidney Axis

Chronic kidney disease fundamentally alters the gut environment, promoting bacterial overgrowth in the small intestine. The accumulation of uremic toxins—whose precursors come from bacterial metabolism—affects the autonomic nervous system controlling gut motility.

This creates a vicious cycle where kidney disease promotes SIBO, and SIBO produces toxins that further damage the kidneys.

7. Dermatological Diseases: Skin Manifestations

The gut-skin axis demonstrates remarkable connections, with acne rosacea patients showing thirteen times greater SIBO exposure than controls. Eradicating SIBO with rifaximin leads to regression of skin lesions in the majority of patients, often maintained for at least nine months.

SIBO increases intestinal permeability, allowing pro-inflammatory cytokines to enter systemic circulation and trigger skin inflammation.

8. Neurological Diseases: Brain-Gut Communication

Perhaps most striking are SIBO’s connections to neurodegenerative diseases:

Parkinson’s Disease: 46% of patients test positive for SIBO. The bacterial overgrowth interferes with levodopa absorption, potentially reducing treatment effectiveness. Some researchers hypothesise SIBO might contribute to Parkinson’s development rather than merely accompanying it.

Alzheimer’s Disease: Studies show 48% SIBO prevalence in Alzheimer’s patients. Abnormal gut bacteria may produce toxic metabolites that cross into the brain, promoting neuroinflammation.

Multiple Sclerosis: Preliminary research in Chinese patients revealed 38% SIBO prevalence, though more studies are needed.

9. Developmental Disorders: Autism Spectrum

Children with autism show 31% SIBO incidence, higher than controls. Notably, autistic children with SIBO demonstrate more severe autism symptoms measured by standardised scales.

The gut microbiome’s role in neurotransmitter production suggests SIBO might influence autism symptom severity through altered brain chemistry.

10. Mental Disorders: Depression and Anxiety

SIBO significantly affects mental health through altered tryptophan metabolism. This amino acid serves as the precursor to serotonin, the neurotransmitter crucial for mood regulation.

SIBO patients demonstrate:

• Higher neuroticism scores
• Lower extroversion
• Increased anxiety and stress levels
• Mild to moderate depression

Treating SIBO with antibiotics improves both gastrointestinal symptoms and mood disorders, supporting the gut-brain connection.

11. Genetic Diseases

Cystic fibrosis patients experience SIBO rates between 31-56%. The CFTR gene mutation leads to abnormal intestinal mucus secretion and reduced motility, creating conditions favourable for bacterial overgrowth.

Familial Mediterranean Fever patients with SIBO show reduced responsiveness to colchicine treatment, possibly due to impaired drug absorption.

12. Gastrointestinal Cancer

Post-operative colorectal cancer patients demonstrate increased SIBO likelihood compared to healthy individuals. The condition aggravates digestive symptoms, though rifaximin treatment provides improvement.

Research reveals higher expression of inflammatory markers (TLR2 and TLR4) in SIBO-positive patients with hepatocellular carcinoma, suggesting SIBO may promote cancer development through chronic inflammation.

Diagnosing SIBO: Testing Methods

Non-Invasive Breath Testing

The most common diagnostic approach involves breath testing after consuming glucose or lactulose. Intestinal bacteria ferment these substrates, producing hydrogen and methane gases that appear in exhaled breath.

Test interpretation:

• Hydrogen rise above 20 ppm within 90 minutes indicates SIBO
• Methane levels ≥10 ppm at any point within 2 hours suggest SIBO
• A double peak pattern also confirms the diagnosis

Gold Standard: Jejunal Aspirate Culture

Direct sampling of small intestinal fluid through endoscopy remains the definitive diagnostic method. Bacterial concentration exceeding 10³ CFU/mL indicates SIBO, though this invasive approach has limitations including potential contamination and specialized laboratory requirements.

Emerging Molecular Techniques

Advanced sequencing of the 16S ribosomal RNA gene enables identification of specific bacterial species involved in SIBO, potentially leading to more targeted treatments.

Treatment Approaches for SIBO

Antibiotic Therapy

Rifaximin represents the most studied antibiotic for SIBO treatment, offering effectiveness with minimal systemic absorption. Other options include metronidazole, ciprofloxacin, and neomycin, typically prescribed empirically due to testing limitations.

Dietary Modifications

The low FODMAP diet supports SIBO treatment by limiting fermentable carbohydrates that feed intestinal bacteria. This approach requires temporary avoidance of:

• Oligosaccharides (fructans, galacto-oligosaccharides)
• Disaccharides (lactose)
• Monosaccharides (fructose)
• Polyols (sorbitol, mannitol)

Alternative Treatments

• Fecal microbiota transplantation shows promise for recurrent cases
• Probiotics may reduce symptom severity, though evidence remains mixed
• Prokinetic medications help improve intestinal motility
• Herbal antimicrobials offer potential alternatives to antibiotics

You can read our blog on how to treat SIBO naturally here.

Addressing Underlying Causes

Successful long-term management requires identifying and correcting factors promoting SIBO:

• Reducing or discontinuing proton pump inhibitors when possible
• Managing diabetes and hypothyroidism
• Correcting anatomical abnormalities
• Treating other gastrointestinal conditions

The Gut-Body Connection: Why SIBO Matters Beyond Digestion

The extensive research linking SIBO to 12 groups of related diseases illuminates how profoundly gut health influences whole-body wellness. The small intestine serves not merely as a digestive organ but as a critical interface between your internal environment and the microbial world.

When bacterial balance shifts in the small intestine, consequences ripple throughout multiple body systems:

• Increased intestinal permeability allows bacterial products into circulation
• Altered nutrient absorption affects every cell
• Changed bacterial metabolites influence distant organs
• Chronic inflammation promotes disease progression
• Neurotransmitter production shifts, affecting brain function

Implications for Healthcare

Understanding SIBO’s broad health impacts should change clinical practice across specialties:

For Gastroenterologists: SIBO testing should be standard in IBS, IBD, and liver disease patients.

For Endocrinologists: Diabetics and hypothyroid patients warrant SIBO screening, particularly with persistent symptoms.

For Cardiologists: Heart failure patients may benefit from gut health assessment.

For Neurologists: Parkinson’s patients not responding well to levodopa should be evaluated for SIBO.

For Dermatologists: Chronic rosacea resistant to standard treatments deserves SIBO consideration.

For Psychiatrists: Treatment-resistant depression with gastrointestinal symptoms might respond to SIBO treatment.

Risk Factors for SIBO Development

Certain conditions and circumstances increase SIBO vulnerability:

• Advanced age (reduced stomach acid production)
• Prolonged proton pump inhibitor use
• Previous abdominal surgery, especially gastric procedures
• Diabetes with autonomic neuropathy
• Hypothyroidism
• Chronic pancreatitis
• Immunosuppression
• Motility disorders
• Anatomical abnormalities (strictures, fistulas, diverticula)

Prevention Strategies

While not all SIBO cases can be prevented, certain measures may reduce risk:

• Limit unnecessary antibiotic use
• Avoid prolonged acid-suppressing medication when possible
• Maintain healthy blood sugar control
• Support gut motility through regular physical activity
• Consume a varied, whole-foods diet
• Manage stress effectively
• Address digestive symptoms promptly

The Future of SIBO Research

Current research limitations include inconsistent diagnostic criteria, varying test sensitivities, and small study populations. Future directions should explore:

• Standardised testing protocols across medical centers
• Molecular techniques for bacterial species identification
• Personalised treatment based on specific bacterial overgrowth patterns
• Long-term outcomes of different treatment approaches
• Preventive strategies for high-risk populations
• Deeper understanding of gut-organ communication pathways

When to Suspect SIBO

Consider SIBO evaluation if you experience:

• Chronic bloating, especially after meals
• Unexplained diarrhoea or constipation
• Food intolerances developing over time
• Nutrient deficiencies despite adequate diet
• Unintentional weight loss
• Persistent fatigue
• Any of the twelve disease groups discussed with accompanying digestive symptoms

Working With Your Healthcare Provider

If you suspect SIBO, approach your healthcare provider with:

• Detailed symptom diary including timing and triggers
• List of current medications, especially PPIs or antibiotics
• Personal and family medical history
• Previous diagnostic test results
• Questions about appropriate testing for your situation

Conclusion: SIBO as a Window into Whole-Body Health

The connections between SIBO and 12 groups of related diseases reveal the small intestine as far more than a digestive organ—it’s a critical player in whole-body health. From brain function to skin appearance, from heart health to mood regulation, the balance of bacteria in your small intestine influences systems throughout your body.

While research continues to evolve, current evidence strongly supports screening for SIBO in numerous conditions beyond traditional gastrointestinal diseases. Early detection and appropriate treatment may improve not only digestive symptoms but also the course of associated conditions.

For patients struggling with chronic, unexplained symptoms—particularly when multiple systems seem affected—SIBO deserves consideration as a potential underlying factor. The gut-body connection runs deeper than previously imagined, and addressing bacterial overgrowth might provide the missing piece in complex health puzzles.

As our understanding of the human microbiome expands, SIBO stands as a prime example of how disruptions in bacterial balance can cascade through multiple body systems. This knowledge empowers both patients and healthcare providers to take a more comprehensive, interconnected view of health and disease.

Reference

Roszkowska  et al., (2024) Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Related Diseases—Current State of Knowledge (click here)

---

Disclaimer: This article provides educational information based on scientific research. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with qualified healthcare providers regarding any medical condition or treatment decisions.